215 related articles for article (PubMed ID: 23874683)
1. Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.
Caldwell JT; Edwards H; Dombkowski AA; Buck SA; Matherly LH; Ge Y; Taub JW
PLoS One; 2013; 8(7):e68601. PubMed ID: 23874683
[TBL] [Abstract][Full Text] [Related]
2. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
[TBL] [Abstract][Full Text] [Related]
3. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.
Ge Y; LaFiura KM; Dombkowski AA; Chen Q; Payton SG; Buck SA; Salagrama S; Diakiw AE; Matherly LH; Taub JW
Leukemia; 2008 Mar; 22(3):521-9. PubMed ID: 18094719
[TBL] [Abstract][Full Text] [Related]
4. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
[TBL] [Abstract][Full Text] [Related]
5. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
[TBL] [Abstract][Full Text] [Related]
6. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
[TBL] [Abstract][Full Text] [Related]
7. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
8. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.
Edwards H; Xie C; LaFiura KM; Dombkowski AA; Buck SA; Boerner JL; Taub JW; Matherly LH; Ge Y
Blood; 2009 Sep; 114(13):2744-52. PubMed ID: 19638627
[TBL] [Abstract][Full Text] [Related]
9. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
[TBL] [Abstract][Full Text] [Related]
10. A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21.
Stepensky P; Brooks R; Waldman E; Revel-Vilk S; Izraeli S; Resnick I; Weintraub M
Pediatr Blood Cancer; 2010 Jul; 54(7):1048-9. PubMed ID: 20108342
[TBL] [Abstract][Full Text] [Related]
11. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
12. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
13. Down syndrome, drug metabolism and chromosome 21.
Taub JW; Ge Y
Pediatr Blood Cancer; 2005 Jan; 44(1):33-9. PubMed ID: 15390307
[TBL] [Abstract][Full Text] [Related]
14. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
Satgé D
Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
[TBL] [Abstract][Full Text] [Related]
15. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines.
Ge Y; Jensen TL; Stout ML; Flatley RM; Grohar PJ; Ravindranath Y; Matherly LH; Taub JW
Cancer Res; 2004 Jan; 64(2):728-35. PubMed ID: 14744791
[TBL] [Abstract][Full Text] [Related]
16. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
17. Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.
Ono R; Hasegawa D; Hirabayashi S; Kamiya T; Yoshida K; Yonekawa S; Ogawa C; Hosoya R; Toki T; Terui K; Ito E; Manabe A
Eur J Pediatr; 2015 Apr; 174(4):525-31. PubMed ID: 25266042
[TBL] [Abstract][Full Text] [Related]
18. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
[TBL] [Abstract][Full Text] [Related]
19. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
Xavier AC; Ge Y; Taub JW
J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
[TBL] [Abstract][Full Text] [Related]
20. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]